Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)
NCT01381211
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
72
Enrollment
OTHER
Sponsor class
Stopped
based on interim analysis results
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
TACE-DEB
DRUG:
90Y-RE
Sponsor
University Hospital, Ghent